Uncategorized
Aerie reports Q2 cash, equivalents and investments of $56.6 million
Aerie Pharmaceuticals reported second-quarter cash, cash equivalents and investments of $56.6 million, according to a company press release. The net loss attributable to common stockholders was $11.8 million, or $0.49 per share, compared with $6.5 million and $6.59 per share during the same period last year, when the company was still privately held, according to the press release.